Some REMS May Still Require Review Extensions In New Model
Executive Summary
FDA’s proposed new review model may cut out the need for some deadline extensions, but if an extensive REMS is expected, the date still could be delayed.
You may also be interested in...
PDUFA Negotiations: FDA Wants To Be Able To Call "Time-Out" During Reviews
FDA has proposed a new application review model that would allow it to call a time-out, which could be used to resolve mid-cycle issues and, the agency argues, potentially bring more predictability to the process.
PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews
FDA wants industry to agree to a set of reasons that would automatically trigger a longer application review as part of the negotiations on reauthorizing the Prescription Drug User Fee Act.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: